01407nas a2200265 4500000000100000008004100001260001200042653000900054653001100063653001200074653002000086653000800106653001200114653001100126653001300137100001800150700001500168700001500183245010800198856006500306300001400371490000700385050001800392520073100410 2006 d c2006///10aSkin10aMexico10aleprosy10aDrug Resistance10aDNA10aDapsone10aBiopsy10aAnalysis1 aLopez Roa R I1 aMorris M F1 aMatsuoka M00aA drug resistant leprosy case detected by DNA sequence analysis from a relapsed Mexican leprosy patient uhttp://www.medigraphic.com/pdfs/lamicro/mi-2006/mi063_4d.pdf a256 - 2590 v48 aLOPEZROA 20063 aA skin biopsy sample was obtained from a relapsed lepromatous leprosy patient from the central area of Mexico. Genes associated with resistance to anti-leprosy drugs were analyzed at codon 53 (ACC-->GCC) in de folP gene, which is known to confer dapsone resistance. No mutations in de rpoB and gyrA, which indicate resistance to rifampicin and floiriquinoles, were detected. This is the first case of dapsone resitant leprosy in Mexico in which the cause of the resistance is shown at genomic level. Evaluation of drug resistance by identifying known mutations in these genes by PCR is simple and reliable. Testing for resistance to anti-leprosy drugs should be performed in relapses or intractable cases for a better outcome.